Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian
immuno-oncology company, will release its first quarter 2025 financial results
on Thursday, May 15th, 2025.

Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO
Gjest Breistein, where they will discuss the results and provide key insights.
In addition, the newly elected Chair, Eric Falcand, will be introduced and he
will share some of his views on the potential of Lytix's unique technology. 

Date: Thursday, May 15th, 2025
Time: 11:15 AM CET

Q&A Session:
We welcome your questions in advance. Please send them to
post@lytixbiopharma.com, and they will be addressed during the Q&A session
following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the
live event by registering here:
https://channel.royalcast.com/landingpage/hegnarmedia/20250515_1/

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our
financial reports page: https://www.lytixbiopharma.com/financial-reports 

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.